Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations-Reference-Cited by-同舟云学术

Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations

Published:2018-01-22 Issue:6 Volume:21 Page:556-563
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Stein Eytan M.¹,Bonifacio Gaetano²,Latremouille-Viau Dominick³,Guerin Annie³,Shi Sherry³,Gagnon-Sanschagrin Patrick³,Briggs Owanate²,Joseph George J.²

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY, USA;

2. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

3. Analysis Group, Inc., Montreal, Quebec, Canada

Funder

Novartis

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1425209

Reference39 articles.

1. National Cancer Institute (NCI). General information about adult aculte myeloid leukemia. Adult Acute Myeloid Leukemia Treatment (PDQ®)- Patient Version. 2016. Available at: http://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq

2. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Acute Myeloid Leukemia (AML). 2016. http://seer.cancer.gov/statfacts/html/amyl.html.

3. American Cancer Society. What are the key statistics about acute myeloid leukemia? 2017. Available at: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html

4. Acute myeloid leukemia: Epidemiology and etiology

5. Acute Myeloid Leukemia

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study;Advances in Therapy;2024-09-06

2. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia;Leukemia & Lymphoma;2024-04-22

3. Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia;Hematology, Transfusion and Cell Therapy;2024-04

4. Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada;Acta Haematologica;2024-02-21

5. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database;Leukemia Research;2023-09